A recent research study conducted by Patanjali has been published in the esteemed Journal of Inflammation Research, a publication by Taylor and Francis. The study highlights a significant advancement in the treatment of psoriasis using Patanjali’s proprietary formulations — Psorogrit tablets and Divya Taila.
Acharya Balkrishna, co-founder of Patanjali, stated that the company’s team of researchers has developed these herbal-based remedies after extensive scientific investigation. According to him, Psorogrit and Divya Taila have shown promising results as effective treatments for psoriasis — a chronic autoimmune skin disorder characterized by red, scaly patches and intense itching.
Traditionally considered incurable, psoriasis has long posed a challenge in dermatological medicine. However, Patanjali claims that its research demonstrates a potential permanent solution using natural herbal compounds.
In the study, Patanjali scientists administered Psorogrit tablets to two different preclinical mouse models of psoriasis — one induced by imiquimod and the other by TPA (12-O-Tetradecanoylphorbol-13-acetate). Divya Taila was applied topically to the affected skin areas. The treatment reportedly yielded positive outcomes, indicating significant improvement in psoriatic symptoms.
This research marks a notable step forward in the use of Ayurvedic medicine for chronic skin conditions, offering new hope for patients worldwide.
